Table 1.
Baseline characteristics of the DOSE trial population
| Variable | n=308 |
|---|---|
| Demographics/medical history | |
| Age | 66 ± 14 |
| Male sex | 73.4% (226) |
| White race | 72.1% (222) |
| Ischemic heart disease | 57.1% (176) |
| Diabetes | 51.3% (158) |
| Gout | 22.4% (69) |
| Cardiac function | |
| Ejection fraction (%) | 30 (30–50) |
| Physical examination findings | |
| Systolic Blood Pressure (mmHg) | 119 ± 20 |
| Heart rate (beats per minute) | 78 ± 16 |
| Jugular venous pressure >12 cm water | 58.6% (171) |
| Edema | 78.9% (243) |
| Rales | 58.2% (178) |
| Medications | |
| ACE or ARB | 64.0% (197) |
| Beta blocker | 83.1% (256) |
| Aldosterone antagonist | 27.9% (86) |
| Laboratory parameters | |
| Sodium (mEq/L) | 138 ± 4 |
| Blood urea nitrogen (mg/dL) | 38 ± 23 |
| eGFR (ml/min/1.73m2) | 55 ± 25 |
| Uric Acid | 9.8 ± 2.6 |
| Hemoglobin (g/dl) | 11.7 ± 2.0 |
| NT-proBNP (pg/mL) | 4435 (2466–9882) |
ACE: Angiotensin converting enzyme inhibitor. ARB: Angiotensin receptor blocker. eGFR: Estimated glomerular filtration rate. NT-proBNP: Amino terminal pro B-type natriuretic peptide. Values presented are mean ± standard deviation, median (quartile 1 – quartile 3) and percentage (absolute number).